The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | B | Blood and blood forming organs | |
2 | B01 | Antithrombotic agents | |
3 | B01A | Antithrombotic agents | |
4 | B01AB | Heparin group |
Code | Title | |
---|---|---|
B01AB01 | Heparin | |
B01AB02 | Antithrombin III | |
B01AB04 | Dalteparin | |
B01AB05 | Enoxaparin | |
B01AB06 | Nadroparin | |
B01AB07 | Parnaparin | |
B01AB08 | Reviparin | |
B01AB09 | Danaparoid | |
B01AB10 | Tinzaparin | |
B01AB11 | Sulodexide | |
B01AB12 | Bemiparin | |
B01AB51 | Heparin, combinations |
Active Ingredient | Description | |
---|---|---|
Antithrombin III |
Antithrombin III is a small glycoprotein anticoagulant that inactivates several enzymes of the coagulation system and accounts for most of the antithrombin activity in plasma. It is a member of the serpin superfamily. |
|
Bemiparin |
Bemiparin is a LMWH obtained by depolymerization of heparin from porcine intestinal mucosa. Bemiparin has confirmed its antithrombotic activity and, at the recommended doses, it does not significantly prolong global clotting tests. |
|
Dalteparin |
Dalteparin is an antithrombotic agent, which acts mainly through its ability to potentiate the inhibition of Factor Xa and thrombin by antithrombin. It has a relatively higher ability to potentiate Factor Xa inhibition than to prolong plasma clotting time (APTT). |
|
Danaparoid |
Danaparoid has been shown both in animal models and in human studies to be an effective antithrombotic substance. At therapeutic doses danaparoid has no or only a minor effect on haemostatic plug formation, platelet function and platelet aggregability with no significant effect on bleeding time at the recommended doses. |
|
Enoxaparin |
Enoxaparin is a LMWH with a mean molecular weight of approximately 4,500 daltons, in which the antithrombotic and anticoagulant activities of standard heparin have been dissociated. The drug substance is the sodium salt and has a high anti-Xa activity. |
|
Heparin |
Heparin is an anticoagulant and acts by inhibiting thrombin and by potentiating the naturally occurring inhibitors of activated Factor X (Xa). |
|
Nadroparin |
Nadroparin is a low-molecular weight heparin. Nadroparin inhibits Factor Xa in particular and thrombin to a lesser extent. Inhibition is partially mediated via the plasma protease inhibitor antithrombin III. Nadroparin has less effect on platelet function and aggregation and only has a minor effect on primary haemostasis compared to heparin. |
|
Parnaparin |
|
|
Reviparin |
Reviparin is a low molecular weight heparin and in clinical terms its action on blood coagulation is the most important biological effect. Reviparin is involved in different phases of blood coagulation. Because of its marked inhibitory action on factor Xa and comparatively low level of anti IIa activity, low molecular weight heparin is at its most active during the preliminary stages of coagulation. |
|
Sulodexide |
|
|
Tinzaparin |
Tinzaparin is an antithrombotic agent. It potentiates the inhibition of several activated coagulation factors, especially Factor Xa, its activity being mediated via antithrombin III. |
Title | Information Source | Document Type | |
---|---|---|---|
AROVI 2,000 IU Solution for injection in pre-filled syringe | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ATENATIV Powder and solvent for solution for infusion | MPI, EU: SmPC | ||
Clexane pre-filled syringes | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CLIVARIN Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
CRUSIA Solution for injection | Health Products Regulatory Authority (ZA) | MPI, Generic | |
FRAGMIN 10.000 IU Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FRAGMIN 100.000 IU Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FRAGMIN 12.500 IU Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FRAGMIN 2.500 IU Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FRAGMIN 5.000 IU Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
FRAGMIN 7.500 IU Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
GHEMAXAN Solution for injection | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
INHIXA 2,000 IU Solution for injection in pre-filled syringe | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
INNOHEP 10,000 anti-Factor Xa IU/ml Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
LOVENOX Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
NOXFIBRA Solution for injection | Web Search | MPI, Generic | |
Orgaran | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ZIBOR 2.500 IU Solution for injection | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
ZIBOR 25.000 IU Solution for injection | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
ZIBOR 3.500 IU Solution for injection | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |